

Proven superior clinical outcomes for people with T1D compared to BGM*1

FLASH-UK RCT

Independent, multicenter, randomized, controlled trial demonstrates how the FreeStyle Libre systems provide superior clinical benefits for people with T1D compared to blood glucose monitoring (BGM).*

STUDY DESIGN & OBJECTIVE



156 people with T1D ≥16 years with A1C ≥7.5% in a randomized open-label trial to determine the efficacy of FreeStyle Libre 2 CGM system vs. BGM at 6 months


SUMMARY OF OUTCOMES AT 6 MONTHS

- Reduced A1C
- Reduced time spent in hypoglycemia (<70 mg/dL)

PRIMARY & SECONDARY END POINTS



- Primary outcome was A1C reduction
- Selected secondary outcomes included Time In Range, hyper- and hypoglycemia duration, patient satisfaction
 - Increased time in range
 - Reduced time spent above range (>180 mg/dL)





RCT=randomized control trial; BGM=blood glucose monitoring; T1D=Type 1 diabetes.

*Data from this study was collected with the outside US version of the FreeStyle Libre 2 system. FreeStyle Libre 3 has the same features as FreeStyle Libre 2 system. Therefore the study data is applicable to both products. † Primary end point: 0.5% greater A1C reduction with the FreeStyle Libre 2 system vs. BGM. ‡Adjusted Mean Between-Group Difference (95% CI). §Time In Range between 70-180 mg/dL.

1. Leelarathna, L. N Engl J Med. (2022): https://doi.org/10.1056/NEJMoa2205650.

1

The FreeStyle Libre systems deliver superior clinical benefits with higher treatment satisfaction compared to BGM*1





Proven to reduce time spent in hypoglycemia (<70 mg/dL) and hyperglycemia (>180 mg/dL) significantly





Significant improvement in overall treatment satisfaction with FreeStyle Libre systems



Reduction in diabetes-related emotional and behavioral burden as measured by GMSS



Improved satisfaction with glucose monitoring as measured by GMSS



PRESCRIBE THE #1 CGM IN THE US[†]



GMSS=Glucose Monitoring Satisfaction Survey; BGM=blood glucose monitoring.

The FreeStyle Libre 2 or 3 apps are only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the apps. Use of the apps may require registration with LibreView.

*Data from this study was collected with the outside US version of the FreeStyle Libre 2 system. FreeStyle Libre 3 has the same features as FreeStyle Libre 2 system. Therefore the study data is applicable to both products. †Data based on the number of patients assigned to each manufacturer based on last filled prescription in US Retail Pharmacy and DME.

1. Leelarathna, L. N Engl J Med. (2022): https://doi.org/10.1056/NEJMoa2205650.

Important Safety Information

FreeStyle Libre 14 day system: Failure to use FreeStyle Libre 14 day system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or https://www.FreeStyle.abbott/us-en/safety-information.html for safety info.

FreeStyle Libre 2 and FreeStyle Libre 3 systems: Failure to use FreeStyle Libre 2 or FreeStyle Libre 3 systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose alarms and readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or https://www.FreeStyle.abbott/ us-en/safety-information.html for safety info.